JP2020518610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518610A5 JP2020518610A5 JP2019560144A JP2019560144A JP2020518610A5 JP 2020518610 A5 JP2020518610 A5 JP 2020518610A5 JP 2019560144 A JP2019560144 A JP 2019560144A JP 2019560144 A JP2019560144 A JP 2019560144A JP 2020518610 A5 JP2020518610 A5 JP 2020518610A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- cancer
- acting
- long
- bias
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000556 agonist Substances 0.000 claims description 136
- 239000003970 toll like receptor agonist Substances 0.000 claims description 43
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 24
- -1 (9H-fluoren-9-yl) methyl Chemical group 0.000 claims description 18
- 102000000588 Interleukin-2 Human genes 0.000 claims description 18
- 108010002350 Interleukin-2 Proteins 0.000 claims description 18
- 229960002751 imiquimod Drugs 0.000 claims description 16
- 102000002689 Toll-like receptor Human genes 0.000 claims description 14
- 108020000411 Toll-like receptor Proteins 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 230000002601 intratumoral effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 238000007910 systemic administration Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 2
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 claims description 2
- 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 2
- 229940124613 TLR 7/8 agonist Drugs 0.000 claims description 2
- 229940124614 TLR 8 agonist Drugs 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 210000000013 bile duct Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 5
- 230000003213 activating effect Effects 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500486P | 2017-05-02 | 2017-05-02 | |
| US62/500,486 | 2017-05-02 | ||
| US201762502051P | 2017-05-05 | 2017-05-05 | |
| US62/502,051 | 2017-05-05 | ||
| PCT/US2018/030714 WO2018204528A1 (en) | 2017-05-02 | 2018-05-02 | Immunotherapeutic tumor treatment method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518610A JP2020518610A (ja) | 2020-06-25 |
| JP2020518610A5 true JP2020518610A5 (enExample) | 2021-06-10 |
| JP7165680B2 JP7165680B2 (ja) | 2022-11-04 |
Family
ID=64016803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560144A Active JP7165680B2 (ja) | 2017-05-02 | 2018-05-02 | 免疫療法的腫瘍治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12054553B2 (enExample) |
| EP (1) | EP3628010A4 (enExample) |
| JP (1) | JP7165680B2 (enExample) |
| KR (1) | KR102785429B1 (enExample) |
| CN (1) | CN110582300B (enExample) |
| AU (1) | AU2018261102B2 (enExample) |
| CA (1) | CA3062291A1 (enExample) |
| IL (1) | IL270329B2 (enExample) |
| MA (1) | MA48862A (enExample) |
| MX (1) | MX2019013071A (enExample) |
| WO (1) | WO2018204528A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110582300B (zh) | 2017-05-02 | 2024-08-02 | 尼克塔治疗公司 | 肿瘤免疫治疗性治疗方法 |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| TWI856997B (zh) * | 2019-01-04 | 2024-10-01 | 丹麥商阿仙帝斯製藥公司 | 模式辨別受體(pattern recognition receptor)促效劑的共軛物 |
| EP3954382A4 (en) * | 2019-04-05 | 2022-12-21 | Sumitomo Pharma Co., Ltd. | Water soluble adjuvant and composition containing same |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| JP2022553370A (ja) * | 2019-10-25 | 2022-12-22 | ネオルーキン セラピューティクス，インコーポレイティド | Ｉｌ－２受容体作動薬の投与方法 |
| WO2021097376A1 (en) | 2019-11-14 | 2021-05-20 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028703A (en) | 1988-03-11 | 1991-07-02 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
| US4810646A (en) | 1984-11-28 | 1989-03-07 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
| US4992540A (en) | 1984-11-28 | 1991-02-12 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| DE10248141B4 (de) * | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
| EP2572715A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| WO2004084949A2 (en) | 2003-03-20 | 2004-10-07 | Xencor | Generating protein pro-drugs using reversible ppg linkages |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| WO2006138572A2 (en) | 2005-06-16 | 2006-12-28 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| US20080044438A1 (en) | 2006-03-17 | 2008-02-21 | Ostroff Gary R | Yeast Cell Particles As Oral Delivery Vehicles For Antigens |
| US20080241139A1 (en) * | 2006-10-31 | 2008-10-02 | Regents Of The University Of Colorado | Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity |
| EP2331140B1 (en) | 2008-08-11 | 2018-07-04 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| US20110274653A1 (en) * | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
| KR20200070407A (ko) | 2010-11-12 | 2020-06-17 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| US20130331443A1 (en) * | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| JP2014506576A (ja) * | 2011-02-10 | 2014-03-17 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド | ４−１ｂｂｌを含むアジュバント組成物 |
| SMT202100191T1 (it) | 2014-02-21 | 2021-05-07 | Nektar Therapeutics | Agonisti selettivi per il-2rbeta in combinazione con un anticorpo anti.ctla-4 o un anticorpo anti-pd-1 |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| KR102619747B1 (ko) * | 2017-01-10 | 2023-12-29 | 넥타르 테라퓨틱스 | Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법 |
| CN110582300B (zh) | 2017-05-02 | 2024-08-02 | 尼克塔治疗公司 | 肿瘤免疫治疗性治疗方法 |
| AU2018316694B2 (en) * | 2017-08-17 | 2025-07-10 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
-
2018
- 2018-05-02 CN CN201880029079.7A patent/CN110582300B/zh active Active
- 2018-05-02 CA CA3062291A patent/CA3062291A1/en active Pending
- 2018-05-02 EP EP18794020.0A patent/EP3628010A4/en active Pending
- 2018-05-02 KR KR1020197035321A patent/KR102785429B1/ko active Active
- 2018-05-02 US US16/610,401 patent/US12054553B2/en active Active
- 2018-05-02 MX MX2019013071A patent/MX2019013071A/es unknown
- 2018-05-02 MA MA048862A patent/MA48862A/fr unknown
- 2018-05-02 AU AU2018261102A patent/AU2018261102B2/en active Active
- 2018-05-02 JP JP2019560144A patent/JP7165680B2/ja active Active
- 2018-05-02 WO PCT/US2018/030714 patent/WO2018204528A1/en not_active Ceased
-
2019
- 2019-10-31 IL IL270329A patent/IL270329B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518610A5 (enExample) | ||
| Zhou et al. | Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer | |
| Li et al. | Small molecules as theranostic agents in cancer immunology | |
| ES2563439T5 (es) | Medios y métodos para tratar LDCBG | |
| JP2022088662A (ja) | ツカレゾールまたはそのアナログを含む組成物 | |
| ES2951650T3 (es) | Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma | |
| JP6224268B2 (ja) | 子宮内膜癌の治療において使用するためのデュオカルマイシンａｄｃ | |
| Geller et al. | Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers | |
| Ma et al. | Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation | |
| JP2015508280A (ja) | ヒト化免疫モノクローナル抗体の変異体 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| US20200069677A1 (en) | Markers for personalized cancer treatment with lsd1 inhibitors | |
| Sui et al. | Peptide drugs: a new direction in cancer immunotherapy | |
| JP2024028988A (ja) | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 | |
| Li et al. | Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis | |
| Lukas et al. | Immunotherapy against gliomas: is the breakthrough near? | |
| WO2021189018A9 (en) | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways | |
| Zhang et al. | Advances in immunotherapies for gliomas | |
| CN111246883A (zh) | 用抗pd-l1抗体和溶瘤病毒治疗三阴性乳癌或结肠直肠癌伴随肝转移 | |
| AU2019242626A1 (en) | Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite | |
| Salgaller et al. | Current status of clinical trials for glioblastoma | |
| JP2017193591A (ja) | 腫瘍細胞選択的抗がん剤 | |
| Jindal | Role of chimeric antigen receptor T cell therapy in glioblastoma multiforme | |
| TW202133887A (zh) | 使用liv1-adc及pd-1拮抗劑之組合療法 | |
| CN114163479A (zh) | 一类治疗癌症用的铂类化合物及其制备方法 |